Introduction {#s1}
============

Hepatitis B virus (HBV) infection is a major global health problem, resulting in 0.5--1.0 million deaths per year [@pone.0086449-Chen1]. The prevalence of chronic HBV infection varies. About 75% of the chronic carriers in the world live in Southeast Asia and East Pacific [@pone.0086449-Custer1]. Due to the introduction of vaccination programs, the prevalence of HBV infection in many countries has gradually been decreasing with consequent decreases in HBV-related hepatocellular carcinoma (HCC) [@pone.0086449-Zidan1]. Although some HBV carriers spontaneously eliminate the virus, about 10--15% of carriers develop liver cirrhosis (LC), liver failure and HCC [@pone.0086449-Pungpapong1]. Moreover, the progression of liver disease was revealed to be associated with the presence of several distinct mutations in HBV infections [@pone.0086449-Kim1]. Genetic variations in *STAT4* and *HLA-DQ* genes were recently identified as host genetic factors in a large-scale genome-wide association study (GWAS) for HBV-related HCC in China [@pone.0086449-Jiang1].

With regard to the genes associated with susceptibility to chronic HBV infection, *HLA-DP* and *HLA-DQ* genes were identified by GWAS in Japanese and Thai populations in 2009 [@pone.0086449-Kamatani1] and 2011 [@pone.0086449-Mbarek1], respectively. In addition, our previous GWAS confirmed and identified the association of SNP markers located on *HLA-DPA1* (rs3077) and *HLA-DPB1* (rs9277535) genes with susceptibility to chronic hepatitis B (CHB) and HBV clearance in Japanese and Korean subjects[@pone.0086449-Nishida1]. The significant associations of *HLA-DP* with CHB and HBV clearance have mainly been detected in Asian populations, such as Japanese [@pone.0086449-Mbarek1], [@pone.0086449-Nishida1], Thai [@pone.0086449-Kamatani1], Chinese [@pone.0086449-Guo1]--[@pone.0086449-Li1], and Korean [@pone.0086449-Nishida1]. In 2012, the association between *HLA-DPA1* gene SNPs and persistent HBV infection was replicated in a Germany non-Asian population for the first time; however, this showed no association with HBV infection [@pone.0086449-Vermehren1]. These results seem to be explained by the fact that allele frequencies of both rs3077 (0.155, 0.587 and 0.743 for C allele, on HapMap CEU, JPT, and YRI) and rs9277535 (0.261, 0.558 and 0.103 for G allele, on HapMap CEU, JPT, and YRI) are markedly different between populations. Moreover, the previous study showed that HBsAg seropositivity rates were higher in Thailand and China (5--12%) than in North America and Europe (0.2--0.5%) [@pone.0086449-Custer1]. These results suggest that comparative analyses of *HLA-DP* alleles and haplotypes in Asian populations would clarify key host factors of the susceptible and protective *HLA-DP* alleles and haplotypes for CHB and HBV clearance. Here, we performed trans-ethnic analyses of *HLA-DP* alleles and haplotypes in Asian populations comprising Japanese, Korean, Hong Kong and Thai individuals. The findings from this study will serve as a base for future functional studies of HLA-DP molecules.

Results {#s2}
=======

Characteristics of studied subjects {#s2a}
-----------------------------------

The characteristics of a total of 3,167 samples, including Japanese, Korean, Hong Kong and Thai subjects, are shown in [Table 1](#pone-0086449-t001){ref-type="table"}. Each population included three groups of HBV patients, resolved individuals and healthy controls. The clinical definitions of HBV patients and resolved individuals are summarized in Materials and Methods. Some of the Japanese and all of the Korean samples overlapped with the subjects in our previous study [@pone.0086449-Nishida1], [@pone.0086449-Sawai1].

10.1371/journal.pone.0086449.t001

###### Number of individuals in this study.
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  Population                                                              Japanese                    Korean    Hong Kong     Thai
  ------------------------------------------------------- ----------------------------------------- ---------- ----------- ----------
  Total number of samples                                                   1,291                      586         661        629
  HBV patients                                                               489                       340         281        390
  IC                                                                         114                        \-         \-          \-
  CH                                                                         147                       175         187        198
  AE                                                                         21                         \-         \-          \-
  LC                                                                         38                         \-         \-          \-
  HCC                                                                        169                       165         94         192
  Mean age (y)                                                              57.1                       44.7       57.9        52.0
  (min-max)                                                               (20--84)                   (18--74)   (32--86)    (21--84)
  Gender (M/F)                                                             338/151                    265/75     239/42     289/101
  Resolved individuals[\*](#nt102){ref-type="table-fn"}                      335                       106         190        113
  HCV (−)                                                                    249                       106         190        113
  HCV (+)                                                                    86                         \-         \-          \-
  Mean age (y)                                                              59.7                       43.1       40.0        48.2
  (min-max)                                                               (18--87)                   (12--66)   (18--60)    (39--66)
  Gender (M/F)                                                             173/162                    61/45      113/77      83/30
  Healthy controls                                                           467                       140         190        126
  Mean age (y)                                             39.0[\*\*](#nt103){ref-type="table-fn"}     33.7       26.2        46.6
  (min-max)                                                               (23--64)                   (1--59)    (16--60)    (38--79)
  Gender (M/F)                                                             370/97                     67/73      87/103      73/53

Abbreviation: IC, Inactive Carrier; CH, Chronic Hepatitis; AE, Acute Exacerbation; LC, Liver Cirrhosis; HCC, Hepatocellular Carcinoma.

\* Resolved individuals were HBsAg negative and HBcAb positive.

\*\* 419 of 467 healthy controls were de-identified, without information on age.

We performed genotyping for *HLA-DPA1* and *HLA-DPB1* in all 3,167 samples, and a total of 2,895 samples were successfully genotyped. The characteristics of successfully genotyped samples are shown in [Table S1](#pone.0086449.s002){ref-type="supplementary-material"}.

Association of *HLA-DPA1* and *HLA-DPB1* alleles in Asian populations {#s2b}
---------------------------------------------------------------------

As for a general Asian population, including 464 Japanese, 140 Korean, 156 Hong Kong, and 122 Thai subjects, five *HLA-DPA1* alleles and twenty-four *HLA-DPB1* alleles were observed ([Table S2](#pone.0086449.s003){ref-type="supplementary-material"}). The frequencies of *HLA-DPA1* and *HLA-DPB1* alleles were similar between Japanese and Korean subjects. On the other hand, the number of alleles with frequencies of 1--2% was larger in Hong Kong and Thai populations, despite the small sample size. Although the frequencies of *HLA-DP* alleles varied in Asian populations, *HLA-DPB1\*05∶01* was the most prevalent with over 30% in all populations.

The associations of *HLA-DPA1* and *HLA-DPB1* alleles with chronic HBV infection (i.e., comparison between HBV patients and healthy controls) are shown in [Table S2](#pone.0086449.s003){ref-type="supplementary-material"}. To avoid false positives caused by multiple testing, the significance levels were corrected based on the numbers of *HLA-DPA1* and *HLA-DPB1* alleles in the focal population. Briefly, the significance level was set at 0.05/(\# of observed alleles at each locus) in each population (see Materials and Methods). With regard to high-risk alleles of *HLA-DPA1*, the most prevalent allele *HLA-DPA1\*02∶02* was significantly associated with susceptibility to HBV infection in Japanese (P = 3.45×10^−4^; OR = 1.39; 95% CI, 1.16--1.68) and Korean subjects (P = 2.66×10^−5^; OR = 1.89; 95% CI, 1.39--2.58), whereas this association was not observed in Hong Kong or Thai subjects. The association of *HLA-DPA1\*02∶01* with susceptibility to HBV infection was significant only in Japanese (P = 2.61×10^−7^; OR = 1.88; 95% CI, 1.46--2.41). The significant association of *HLA-DPA1\*01∶03* with protection against HBV infection was commonly observed among four Asian populations ([Table S2](#pone.0086449.s003){ref-type="supplementary-material"}). The pooled OR and 95% CI were 0.51 and 0.41--0.63, respectively in a meta-analysis (P = 3.15×10^−10^) ([Fig. S1A](#pone.0086449.s001){ref-type="supplementary-material"}).

As shown in [Table S2](#pone.0086449.s003){ref-type="supplementary-material"}, *HLA-DPB1* shows higher degree of polymorphism than *HLA-DPA1*. The most common allele in Asian populations, *HLA-DPB1\*05∶01*, was significantly associated with HBV susceptibility in both Japanese and Korean subjects. Although *HLA-DPB1\*05∶01* showed no significant association in the Hong Kong and Thai populations, the same direction of association (i.e., HBV susceptibility) was observed. Meta-analysis of the four populations revealed a significant association between *HLA-DPB1\*05∶01* and susceptibility to HBV infection (P = 1.51×10^−4^; OR = 1.45; 95% CI, 1.19--1.75) ([Fig. S1B](#pone.0086449.s001){ref-type="supplementary-material"}). The frequency of *HLA-DPB1\*09∶01* was significantly elevated in Japanese HBV patients (15.7%) as compared with healthy controls (8.7%) (P = 3.70×10^−6^; OR = 1.94; 95% CI, 1.45--2.62), and this association was most significant (i.e., the smallest P value) in the Japanese population. Because of lower allele frequencies of *HLA-DPB1\*09∶01* or lack of statistical power in the other populations, no significant associations were observed. A common allele in Thai subjects, *HLA-DPB1\*13∶01*, was significantly associated with susceptibility to HBV infection (P = 2.49×10^−4^; OR = 2.17; 95% CI, 1.40--3.47) with the same direction of associations in Japanese and Hong Kong (OR = 1.52 and 1.40, respectively).

*HLA-DPB1\*04∶02* was identified as the most protective allele for HBV infection in Japanese (P = 1.59×10^−7^; OR = 0.37; 95% CI, 0.24--0.55) and Korean subjects (P = 1.27×10^−7^; OR = 0.19; 95% CI, 0.10--0.38). Both *HLA-DPB1\*02∶01* and *HLA-DPB1\*04∶01* were also significantly associated with protection in the Japanese population, and the former was significantly associated with protection in Hong Kong subjects (P = 9.17×10^−4^; OR = 0.49; 95% CI, 0.32--0.76). This common allele among four Asian populations, *HLA-DPB1\*02∶01*, showed a significant association with protection against HBV infection (P = 5.22×10^−6^; OR = 0.68; 95% CI, 0.58--0.81) in a meta-analysis ([Fig. S1B](#pone.0086449.s001){ref-type="supplementary-material"}).

The frequencies of associated *HLA-DP* alleles in a comparison of HBV patients with healthy controls ([Table S2](#pone.0086449.s003){ref-type="supplementary-material"}) or with HBV-resolved individuals ([Table S3](#pone.0086449.s004){ref-type="supplementary-material"}) were similar in all four Asian populations. In the Japanese population, the associations of susceptible and protective *HLA-DPB1* alleles to chronic HBV infection seem weaker in the comparison of HBV patients with HBV-resolved individuals than in the comparison of HBV patients with healthy controls. Moreover, the results of association analyses showed no difference in the comparison of HBV patients with HBV-resolved individuals, including or excluding HCV positive individuals ([Table S3](#pone.0086449.s004){ref-type="supplementary-material"}). In contrast, the association became stronger in the comparison of HBV patients with HBV-resolved individuals among the Korean subjects. The protective allele *HLA-DPB1\*04∶01* was also identified to have a strong association with HBV clearance in Hong Kong subjects ([Table S3](#pone.0086449.s004){ref-type="supplementary-material"}). Moreover, in Hong Kong subjects, the *HLA-DPB1\*05∶01* associated with the risk for HBV infection showed lower frequency in HBV-resolved individuals (42.9%) than in the healthy controls (48.1%), which accounts for a strong association in the comparison of HBV patients with HBV-resolved individuals (P = 6.24×10^−3^; OR = 1.64; 95% CI, 1.14--2.36). Although the number of samples was insufficient, *HLA-DP\*100∶01* showed a significant association with protection against HBV infection in the Hong Kong population (P = 3.05×10^−6^; OR = 0.03; 95% CI, 0.0007--0.20).

As for disease progression in CHB patients among Asian populations, a protective effect of *HLA-DPB1\*02∶01* on disease progression was observed in the Japanese (P = 4.26×10^−5^; OR = 0.45; 95% CI, 0.30--0.67) and Korean populations (P = 8.74×10^−4^; OR = 0.47; 95% CI, 0.29--0.75) ([Table S4](#pone.0086449.s005){ref-type="supplementary-material"}). Multivariate logistic regression analysis adjusted for age and sex revealed that the number of *DPB1\*02∶01* alleles (i.e., 0, 1, or 2) was significantly associated with disease progression in CHB patients in Japanese (P = 1.77×10^−4^; OR = 0.47; 95% CI, 0.32--0.70) ([Table 2](#pone-0086449-t002){ref-type="table"}). Moreover, protective effects of *DPB1\*02∶01* on disease progression in Asian populations (P = 1.55×10^−7^; OR = 0.50; 95% CI, 0.39--0.65) were detected in a multivariate logistic regression analysis adjusted for age, gender, and population ([Table 2](#pone-0086449-t002){ref-type="table"}).

10.1371/journal.pone.0086449.t002

###### Association of number of *DPB1* [\*](#nt104){ref-type="table-fn"} *02∶01* alleles (i.e., 0, 1 or 2) with disease progression in CHB patients assessed by multivariate logistic regression analysis adjusted for age and sex.
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  Population                                P value        OR (95% CI)
  -------------------------------------- ------------- -------------------
  Japanese                                 0.000177     0.47 (0.32--0.70)
  Korean                                   0.025358     0.55 (0.33--0.93)
  Hong Kong                                0.040842     0.46 (0.22--0.97)
  Thai                                     0.087782     0.58 (0.31--1.08)
  All[\*](#nt104){ref-type="table-fn"}    1.55×10^−7^   0.50 (0.39--0.65)

\*Population was adjusted using dummy variables.

Associations of *DPA1-DPB1* haplotypes in Asian populations {#s2c}
-----------------------------------------------------------

The estimated frequencies of *HLA DPA1-DPB1* haplotypes are shown in [Table S5](#pone.0086449.s006){ref-type="supplementary-material"}. The most frequent haplotype among the four Asian populations was *DPA1\*02∶02-DPB1\*05∶01*. The number of haplotypes with low frequencies of 1--2% was 10 in both Japanese and Korean subjects, whereas more haplotypes appeared with frequencies of 1--2% in Hong Kong and Thai subjects. The associations of *DPA1-DPB1* haplotypes with HBV infection are shown in [Table S5](#pone.0086449.s006){ref-type="supplementary-material"}. In the Japanese population, *DPA1\*02∶01-DPB1\*09∶01* showed the most significant association with susceptibility to HBV infection (P = 3.38×10^−6^; OR = 1.95; 95% CI, 1.46--2.64). The most common haplotype in the four Asian populations, *DPA1\*02∶02-DPB1\*05∶01*, was found to be significantly associated with susceptibility to HBV infection in the Japanese and Korean subjects (P = 7.40×10^−4^; OR = 1.37; 95% CI, 1.14--1.66 for Japanese, and P = 4.50×10^−6^; OR = 2.02; 95% CI, 1.48--2.78 for Korean). In the Thai subjects, *HLA-DPB1\*13∶01* was the most significant risk allele for HBV infection ([Table S2](#pone.0086449.s003){ref-type="supplementary-material"}); however, no significant associations were found for the three different haplotypes bearing *HLA-DPB1\*13∶01*: *DPA1\*02∶01-DPB1\*13∶01*, *DPA1\*02∶02-DPB1\*13∶01*, and *DPA1\*04∶01-DPB1\*13∶01*,indicating that the association of *HLA-DPB1\*13∶01* with susceptibility to HBV infection did not result from a specific *DPA1-DPB1* haplotype or combination with a specific *DPA1* allele.

In the Japanese population, both haplotypes *DPA1\*01∶03-DPB1\*04∶01* and *DPA1\*01∶03-DPB1\*04∶02* showed significant associations with protection against HBV infection (P = 1.17×10^−5^; OR = 0.32; 95% CI, 0.18--0.56 for *DPA1\*01∶03-DPB1\*04∶01* and P = 1.95×10^−7^; OR = 0.37; 95% CI, 0.24--0.55 for *DPA1\*01∶03-DPB1\*04∶02*). In the Korean subjects, a significant association of *DPA1\*01∶03-DPB1\*04∶02* was also demonstrated; however, no association was observed for *DPA1\*01∶03-DPB1\*04∶01*. Because the observed number of each haplotype was small, none of the other haplotypes showed a significant association with protection against HBV infection.

In order to identify trans-ethnic DPA1-DPB1 haplotypes associated with HBV infection, a meta-analysis was performed. A meta-analysis further revealed that the *DPA1\*01∶03-DPB1\*02∶01* haplotype was significantly associated with protection against HBV infection (P = 1.45×10^−5^; OR = 0.69; 95% CI, 0.58--0.82) ([Fig. S1C](#pone.0086449.s001){ref-type="supplementary-material"}).

Discussion {#s3}
==========

Among 2.2 billion individuals worldwide who are infected with HBV, 15% of these are chronic carriers. Of chronic carriers, 10--15% develops LC, liver failure and HCC, and the remaining individuals eventually achieve a state of nonreplicative infection, resulting in HBsAg negative and anti-HBc positive, i.e. HBV-resolved individuals. To identify host genetic factors associated with HBV-related disease progression may lead HBV patients to discriminate individuals who need treatment.

The *HLA-DPA1* and *HLA-DPB1* genes were identified as host genetic factors significantly associated with CHB infection, mainly in Asian populations [@pone.0086449-Kamatani1]--[@pone.0086449-Li1], and not in European populations [@pone.0086449-Vermehren1]. In the previous association analyses of *HLA-DPB1* alleles with HBV infection, one risk allele *HLA-DPB1\*05∶01* (OR = 1.52; 95% CI, 1.31--1.76), and two protective alleles, *HLA-DPB1\*04∶01* (OR = 0.53; 95% CI, 0.34--0.80) and *HLA-DPB1\*04∶02* (OR = 0.47; 95% CI, 0.34--.64), were identified in the Japanese population [@pone.0086449-Kamatani1]. In this study, we further identified a new risk allele *HLA-DPB1\*09∶01* (OR = 1.94; 95% CI, 1.45--2.62) for HBV infection and a new protective allele *HLA-DPB1\*02∶01* (OR = 0.71; 95% CI, 0.56--0.89) in the Japanese population, in addition to the previously reported alleles ([Table S2](#pone.0086449.s003){ref-type="supplementary-material"}) [@pone.0086449-Kamatani1]. The discrepancy in the association of *HLA-DPB1\*09∶01* allele with risk for HBV infection in a previous study [@pone.0086449-Kamatani1] results from the elevated frequency of *HLA-DPB1\*09∶01* in the controls (12.2%), which is higher than our controls (8.7%). In this study, healthy subjects were recruited as controls. In contrast, individuals that were registered in BioBank Japan as subjects with diseases other than CHB were recruited as controls in the previous study [@pone.0086449-Kamatani1], which may have included patients with diseases with which *HLA-DPB1\*09∶01* is associated. Although no significant association of *HLA-DPB1\*09∶01* with risk for HBV infection was observed in the Korean subjects, *HLA-DPB1\*09∶01* appears to have a susceptible effect on HBV infection, as it showed the same direction of association. When the association analyses in Japanese and Korean subjects were combined in meta-analysis, the association was statistically significant (P = 1.36×10^−6^; OR = 1.97; 95% CI, 1.50--2.59). Thus, *HLA-DPB1\*09∶01* may be a Northeast Asian-specific allele associated with risk for HBV infection.

Moreover, a significant association of *HLA-DPB1\*13∶01* with risk of HBV infection (OR = 2.17; 95% CI, 1.40--3.47) was identified in the Thai subjects. However, the frequency of *HLA-DPB1\*13∶01* in Thai healthy controls (11.5% in the present study) reportedly varies, ranging from 15.4% to 29.5%, due to the population diversity [@pone.0086449-Chandanayingyong1]--[@pone.0086449-Maneemaroj1]. Therefore, a replication analysis is required to confirm the association of *HLA-DPB1\*13∶01* with HBV infection in the Thai subjects. There were four other marginally associated *HLA-DPB1* alleles with low allele frequencies below 5% in HBV patients and healthy controls, including *HLA-DPB1\*28∶01*, *-DPB1\*31∶01*, *-DPB1\*100∶01*, and *-DPB1\*105∶01*, in the Hong Kong and Thai subjects. Because these infrequent alleles may have resulted from false positive associations, the association needs to be validated in a large number of subjects.

*HLA-DPB1\*02∶01* showed a significant association with protection against HBV infection in both Japanese and Hong Kong populations ([Table S2](#pone.0086449.s003){ref-type="supplementary-material"}); however, the *HLA-DPB1\*02∶01* allele was not associated with HBV infection in the previous study [@pone.0086449-Kamatani1]. Although *HLA-DPB1\*02∶01* showed no association in either Korean or Thai populations, a significant association of *HLA-DPB1\*02∶01* with protection against HBV infection among four Asian populations was detected in meta-analysis (P = 5.22×10^−6^; OR = 0.68; 95% CI, 0.58--0.81) ([Fig. S1B](#pone.0086449.s001){ref-type="supplementary-material"}). We therefore conclude that the present finding is not a false positive.

A recent report showed that *HLA-DPB1\*02∶01∶02*, *\*02∶02*, *\*03∶01∶01*, *\*04∶01∶01*, *\*05∶01*, *\*09∶01*, and *\*14∶01* were significantly associated with response to booster HB vaccination in Taiwan neonatally vaccinated adolescents [@pone.0086449-Wu1]. The *HLA-DPB1\*02∶01∶02*, *\*02∶02*, *\*03∶01∶01*, *\*04∶01∶01*, and *\*14∶01* were significantly more frequent in recipients whose post-booster titers of antibodies against HBV surface antigen (anti-HBs) were detectable, on the other hand, *HLA-DPB1\*05∶01* and *\*09∶01* were significantly more frequent in recipients who were undetectable. Moreover, the *HLA-DPB1\*05∶01* and *\*09∶01* significantly increase the likelihoods of undetectable pre-booster anti-HBs titers. These results seem consistent with our findings, in which *HLA-DPB1\*05∶01* and *\*09∶01* are associated with susceptibility to chronic hepatitis B infection.

We also identified a protective effect of *HLA-DPB1\*02∶01* allele on disease progression in Asian populations. Previous studies identified the association of HLA class II genes including *HLA-DQ* and *HLA-DR* with development of HBV related hepatocellular carcinoma in the Chinese population [@pone.0086449-Jiang1], [@pone.0086449-Hu1], [@pone.0086449-Li2]. In this study using Japanese and Korean samples, we identified significant associations between *HLA-DPB1\*02∶01* and disease progression in CHB patients (P = 4.26×10^−5^; OR = 0.45; 95% CI, 0.30--0.67, for Japanese and P = 8.74×10^−4^; OR = 0.47; 95% CI, 0.29--0.75 for Korean) ([Table S4](#pone.0086449.s005){ref-type="supplementary-material"}). Although the association of *HLA-DPB1\*02∶01* with disease progression was weaker after adjustment for age and gender in Korean subjects (P = 2.54×10^−2^; OR = 0.55; 95% CI, 0.33--0.93), the same direction of association was observed (i.e. protective effect on disease progression) ([Table 2](#pone-0086449-t002){ref-type="table"}). The protective effects of *HLA-DPB1\*02∶01* on disease progression showed a significant association after adjustment for age and gender in the Japanese population (P = 1.77×10^−4^; OR = 0.47; 95% CI, 0.32--0.70); moreover, a significant association between *HLA-DPB1\*02∶01* was observed among four Asian populations, under which population was adjusted by using dummy variables in a multivariate logistic regression analysis (P = 1.55×10^−7^; OR = 0.50; 95% CI, 0.39--0.65) ([Table 2](#pone-0086449-t002){ref-type="table"}).

The *HLA-DPA1* and *HLA-DPB1* belong to the HLA class II alpha and beta chain paralogues, which make a heterodimer consisting of an alpha and a beta chain on the surface of antigen presenting cells. This HLA class II molecule plays a central role in the immune system by presenting peptides derived from extracellular proteins. We identified two susceptible haplotypes (*DPA1\*02∶02-DPB1\*05∶01* and *DPA1\*02∶01-DPB1\*09∶01*) and three protective haplotypes (*DPA1\*01∶03-DPB1\*04∶01*, *DPA1\*01∶03-DPB1\*04∶02*, and *HLA-DPA1\*01∶03-DPB1\*02∶01*) to chronic hepatitis B infection, which may result in different binding affinities between HLA-DP subtypes and extracellular antigens. Although functional analyses of HLA-DP subtypes to identify HBV-related peptides are not fully completed, identification of susceptible and protective haplotypes as host genetic factors would lead us to understand the pathogenesis of HBV infection including viral factors.

In summary, we identified a new risk allele *HLA-DPB1\*09∶01*, which was specifically observed in Northeast Asian populations, Japanese and Korean. Moreover, a new protective allele *HLA-DPB1\*02∶01* was identified among four Asian populations: Japanese, Korean, Hong Kong and Thai. The protective allele *HLA-DPB1\*02∶01* was associated with both chronic HBV infection and disease progression in chronic HBV patients. Identification of a total of five alleles, including two risk alleles (*DPB1\*09∶01* and *DPB1\*05∶01*) and three protective alleles (*DPB1\*04∶01*, *DPB1\*04∶02* and *DPB1\*02∶01*), would enable HBV-infected individuals to be classified into groups according to the treatment requirements. Moreover, the risk and protective alleles for HBV infection and disease progression, identified in this study by means of trans-ethnic association analyses, would be key host factors to recognize HBV-derived antigen peptides. The present results may lead to subsequent functional studies into HLA-DP molecules and viral factors in order to understand the pathogenesis of HBV infection and development of hepatocellular carcinoma.

Materials and Methods {#s4}
=====================

Ethics Statement {#s4a}
----------------

All study protocols conform to the relevant ethical guidelines, as reflected in the *a priori* approval by the ethics committee of National Center for Global Health and Medicine, and by the ethics committees of all participating universities and hospitals, including The University of Tokyo, Japanese Red Cross Kanto-Koshinetsu Block Blood Center, The University of Hong Kong, Chulalongkorn University, Yonsei University College of Medicine, Nagoya City University Graduate School of Medical Sciences, Musashino Red Cross Hospital, Tokyo Medical and Dental University, Teine Keijinkai Hospital, Hokkaido University Graduate School of Medicine, Kurume University School of Medicine, Okayama University Graduate School of Medicine, Yamaguchi University Graduate School of Medicine, Tottori University, Kyoto Prefectural University of Medicine, Osaka City University Graduate School of Medicine, Nagoya Daini Red Cross Hospital, Ehime University Graduate School of Medicine, Kanazawa University Graduate School of Medicine, National Hospital Organization Osaka National Hospital, Iwate Medical University, Kawasaki Medical College, Shinshu University School of Medicine, Saitama Medical University, Kitasato University School of Medicine, Saga Medical School, and University of Tsukuba.

Written informed consent was obtained from each patient who participated in this study and all samples were anonymized. For Japanese healthy controls, 419 individuals were de-identified with information about gender, and all were recruited after obtaining verbal informed consent in Tokyo prior to 1990. For the 419 Japanese healthy individuals, written informed consent was not obtained because the blood sampling was conducted before the "Ethical Guidelines for Human Genome and Genetic Sequencing Research" were established in Japan. Under the condition that DNA sample is permanently de-linked from the individual, this study was approved by the Research Ethics Committee of National Center for Global Health and Medicine.

Characteristics of studied subjects {#s4b}
-----------------------------------

All of the 3,167 genomic DNA samples were collected from individuals with HBV, HBV-resolved individuals (HBsAg-negative and anti-HBc-positive) and healthy controls at 26 multi-center hospitals throughout Japan, Korea, Hong Kong, and Thailand ([Table 1](#pone-0086449-t001){ref-type="table"}). In a total of 1,291 Japanese and 586 Korean samples, 1,191 Japanese individuals and all 586 Korean individuals were included in our previous study [@pone.0086449-Nishida1]. With regard to additional Japanese individuals, we collected samples from 48 healthy controls at Kohnodai Hospital, and 52 HBV patients at Okayama University Hospital and Ehime University Hospital, including 26 individuals with LC and 26 individuals with HCC. A total of 661 Hong Kong samples and 629 Thai samples were collected at Queen Mary Hospital and Chulalongkorn University, respectively.

HBV status was measured based on serological results for HBsAg and anti-HBc with a fully automated chemiluminescent enzyme immunoassay system (Abbott ARCHITECT; Abbott Japan, Tokyo, Japan, or LUMIPULSE f or G1200; Fujirebio, Inc., Tokyo, Japan). For clinical staging, inactive carrier (IC) state was defined by the presence of HBsAg with normal ALT levels over 1 year (examined at least four times at 3-month intervals) and without evidence of liver cirrhosis. Chronic hepatitis (CH) was defined by elevated ALT levels (\>1.5 times the upper limit of normal \[35 IU/L\]) persisting over 6 months (by at least 3 bimonthly tests). Acute exacerbation (AE) of chronic hepatitis B was defined as an elevation of ALT to more than 10 times the upper limit of normal (ULN, 58 IU/L) and bilirubin to at least three times ULN (15 µmol/L). LC was diagnosed principally by ultrasonography (coarse liver architecture, nodular liver surface, blunt liver edges and hypersplenism), platelet counts\<100,000/cm^3^, or a combination thereof. Histological confirmation by fine-needle biopsy of the liver was performed as required. HCC was diagnosed by ultrasonography, computerized tomography, magnetic resonance imaging, angiography, tumor biopsy or a combination thereof.

The Japanese control samples from HBV-resolved subjects (HBsAg-negative and anti-HBc-positive) at Nagoya City University-affiliated healthcare center were used by comprehensive agreement (anonymization in a de-identified manner) in this study. Some of the unrelated and anonymized Japanese healthy controls were purchased from the Japan Health Science Research Resources Bank (Osaka, Japan). One microgram of purified genomic DNA was dissolved in 100 µl of TE buffer (pH 8.0) (Wako, Osaka, Japan), followed by storage at −20°C until use.

Genotyping of *HLA-DPA1* and *HLA-DPB1* alleles {#s4c}
-----------------------------------------------

High resolution (4-digit) genotyping of *HLA-DPA1* and *-DPB1* alleles was performed for HBV patients, resolved individuals, and healthy controls in Japan, Korea, Hong Kong, and Thailand. LABType SSO HLA DPA1/DPB1 kit (One Lambda, CA) and a Luminex Multi-Analyte Profiling system (xMAP; Luminex, Austin, TX) were used for genotyping, in according with the manufacturer\'s protocol. Because of the small quantity of genomic DNA in some Korean samples, we performed whole genome amplification for a total of 486 samples using GenomiPhi v2 DNA Amplification kit (GE Healthcare Life Sciences, UK), in accordance with the manufacturer\'s instruction.

A total of 2,895 samples were successfully genotyped and characteristics of these samples are summarized in [Table S1](#pone.0086449.s002){ref-type="supplementary-material"}.

Statistical analysis {#s4d}
--------------------

Fisher\'s exact test in two-by-two cross tables was used to examine the associations between *HLA-DP* allele and chronic HBV infection or disease progression in chronic HBV patients, using statistical software R2.9. To avoid false-positive results due to multiple testing, significance levels were adjusted based on the number of observed alleles at each locus in each population. For *HLA-DPA1* alleles, the number of observed alleles was 3 in Japanese, 4 in Korean, 5 in Hong Kong, and 5 in Thai subjects. Therefore, the significant levels for α were set at α = 0.05/3 in Japanese, α = 0.05/4 in Korean, α = 0.05/5 in Hong Kong, and α = 0.05/5 in Thai subjects. In the same way, significant levels for *HLA-DPB1* alleles were α = 0.05/10, 0.05/11, 0.05/12, and 0.05/16, respectively. Multivariate logistic regression analysis adjusted for age and sex (used as independent variables) was applied to assess associations between the number of *DPB1\*02∶01* alleles (i.e., 0, 1, or 2) and disease progression in CHB patients. To examine the effect of *DPB1\*02∶01* allele on disease progression in all populations, population was further adjusted by using three dummy variables (i.e., (c1, c2, c3) = (0, 0, 0) for Japanese, (1, 0, 0) for Korean, (0, 1, 0) for Hong Kong, and (0, 0, 1) for Thai) in a multivariate logistic regression analysis. We obtained the following regression equation: logit(p) = −3.905+0.083\*age+(−0.929)\*sex+(−0.684)\**DPB1\*02∶01*+1.814\*c1+(−0.478)\*c2+0.782\*c3. Significance levels in the analysis of disease progression in CHB patients were set as α =  0.05/10 in Japanese, α = 0.05/11 in Korean, α = 0.05/15 in Hong Kong, and α = 0.05/15 in Thai subjects. The phase of each individual (i.e., a combination of two *DPA1-DPB1* haplotypes) was estimated using PHASE software [@pone.0086449-Stephens1], assuming samples are selected randomly from a general population. In comparison of the estimated *DPA1-DPB1* haplotype frequencies, significant levels were set as α = 0.05/14 in Japanese, α = 0.05/17 in Korean, α = 0.05/17 in Hong Kong, and α = 0.05/18 in Thai subjects. Meta-analysis was performed using the DerSimonian-Laird method (random-effects model) in order to calculate pooled OR and its 95% confidence interval (95% CI). We applied meta-analysis for alleles with frequency\>1% in all four Asian populations. The significance levels in meta-analysis were adjusted by the total number of statistical tests; α = 0.05/20 for *DPA1* alleles, α = 0.05/57 for *DPB1* alleles, and α = 0.05/74 for *DPA1-DPB1* haplotypes.
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